# US 2008/0187517 A1 · Use of Serum Albumin Binding Peptides Conjugates for the Preparation of a Medicament

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0187517 A1
- Document ID: US20080187517A1
- Status: Published application
- Kind: A1
- Application number: 11/547,888
- Filed: 2005-04-06
- Published: 2008-08-07
- Earliest claimed: 2004-04-06
- Assignees: Affibody AB
- Inventors: Nina Herne
- Web page: https://patentgrep.com/patent/US20080187517A1

## CPC

- C07K 16/18: against material from animals or humans
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61P 37/02: Immunomodulators
- A61P 39/00: General protective or antinoxious agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/315: from Streptococcus (G), e.g. Enterococci
- C07K 14/47: from mammals
- C07K 14/4726: {Lectins}
- C07K 14/535: Granulocyte CSF; Granulocyte-macrophage CSF
- C07K 14/555: Interferons [IFN]
- C07K 14/575: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K14/665, e.g. corticotropin C07K14/695)
- C07K 14/61: Growth hormone [GH], i.e. somatotropin
- C07K 14/755: Factors VIII {, e.g. factor VIII C (AHF), factor VIII Ag (VWF)}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A new use of a molecule comprising at least one moiety which is a biologically active protein and at least one moiety capable of binding to a serum albumin of a mammal is provided, for preparation of a medicament which elicits no or a reduced immune response upon administration to the mammal, as compared to the immune response elicited upon administration to the mammal of the biologically active protein per se. Also provided is a method of reducing or eliminating the immune response elicited upon administration of a biologically active protein to a human or non-human mammal, which comprises coupling the polypeptide to at least one moiety capable of binding to a serum albumin of the mammal.

## Claims

### Claim 1

A method of preparing a medicament which elicits no or a reduced immune response upon administration to a mammal as compared to the immune response elicited upon administration to the mammal of the biologically active protein per se, comprising combining a molecule comprising at least one moiety which is a biologically active protein and at least one moiety capable of binding to a serum albumin of a mammal with a pharmaceutically acceptable carrier.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the moiety capable of binding to a serum albumin of a mammal is a compound selected from proteins and polypeptides.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the moiety capable of binding to a serum albumin of a mammal is a naturally occurring polypeptide or an albumin-binding fragment or derivative thereof.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the naturally occurring polypeptide is selected from the group consisting of streptococcal M proteins M1/Emm1, M3/Emm3, M12/Emm12, EmmL55/Emm55, Emm49/EmmL49 and Protein H; streptococcal proteins G, MAG and ZAG; and PPL and PAB from Finegoldia magna.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the moiety capable of binding to a serum albumin of a mammal is streptococcal protein G or an albumin-binding fragment or derivative thereof.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the moiety capable of binding to a serum albumin of a mammal is the ABD domain of streptococcal protein G, or an albumin-binding fragment or derivative thereof.

### Claim 7 (depends on 2)

The method according to claim 2, wherein the moiety capable of binding to a serum albumin of a mammal is an albumin-binding polypeptide comprising from about 5 to about 214 amino acid residues.

### Claim 8 (depends on 7)

The method according to claim 7 in which the albumin-binding polypeptide comprises from about 5 to about 46 amino acid residues

### Claim 9 (depends on 7)

The method according to claim 7, wherein the albumin-binding peptide comprises from about 10 to about 20 amino acid residues.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the albumin-binding peptide comprises an amino acid sequence selected from DICLPRWGCLW, DLCLRDWGCLW and DICLARWGCLW and albumin-binding derivatives thereof.

### Claim 11 (depends on 1)

The method of claim 1, in which the moiety capable of binding to a serum albumin of a mammal is arranged to enhance its binding with human serum albumin.

### Claim 12 (depends on 11)

The method according to claim 11 in which the moiety capable of binding to a serum albumin of a mammal is capable of interacting at least one of, and preferably all of, residues Phe-228, Ala-229, Ala-322, Val-325, Phe-326, and Met-329 from human serum albumin so as to enhance binding of the molecule to albumin.

### Claim 13 (depends on 12)

The method according to claim 12 in which the moiety capable of binding to a serum albumin of a mammal includes an amino acid residue which forms an interaction with the methionine residue at position 329 of human serum albumin so as to enhance binding of the molecule to albumin.

### Claim 14 (depends on 11)

The method according to claim 11 in which the moiety capable of binding to a serum albumin of a mammal includes an amino acid residue which forms an interaction with helix 7 in the human serum albumin domain IIB so as to enhance binding of the molecule to albumin.

### Claim 15 (depends on 11)

The method according to claim 11 in which the moiety capable of binding to a serum albumin of a mammal includes an amino acid residue which forms an interaction with residues in human serum albumin domain IIA so as to enhance binding of the molecule to albumin.

### Claim 16 (depends on 11)

The method according to claim 11 in which the moiety capable of binding to a serum albumin of a mammal includes an amino acid residue which forms an interaction with residues between helices 2 and 3 of human serum albumin so as to enhance binding of the molecule to albumin.

### Claim 17 (depends on 1)

The method according to claim 1, wherein the moiety capable of binding to a serum albumin of a mammal is a non-proteinaceous organic compound.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the non-proteinaceous organic compound is selected from albumin-binding non-steroidal anti-inflammatory drugs (NSAIDs); diclofenac; salicylic acid; warfarin; propofol; and halothane.

### Claim 19 (depends on 18)

The method according to claim 18 in which the albumin-binding NSAID is ibuprofen or carprofen.

### Claim 20 (depends on 1)

The method according to claim 1, wherein the molecule has a first site, which site has a biologically useful activity, and a second site, which mediates binding of the molecule to a serum albumin of a mammal.

### Claim 21 (depends on 20)

The method according to claim 20 in which the first site is from a biologically active protein.

### Claim 22 (depends on 1)

The method according to claim 1, wherein the molecule has a binding affinity for the serum albumin such that the KD of the interaction is less than or equal to 10−6 M.

### Claim 23 (depends on 22)

The method according to claim 22, wherein the molecule has a binding affinity for the serum albumin of less than or equal to 10−7 M.

### Claim 24 (depends on 22)

The method according to claim 22, wherein the molecule has a binding affinity for the serum albumin of less than or equal to 10−8 M.

### Claim 25 (depends on 22)

The method according to claim 22, wherein the molecule has a binding affinity for the serum albumin of less than or equal to 10−9 M.

### Claim 26 (depends on 22)

The method according to claim 22, wherein the molecule has a binding affinity for the serum albumin of less than or equal to 10−10 M.

### Claim 27 (depends on 22)

The method according to claim 22, wherein the molecule has a binding affinity for the serum albumin of less than or equal to 10−11 M.

### Claim 28 (depends on 22)

The method according to claim 22, wherein the molecule has a binding affinity for the serum albumin of less than or equal to 10−12 M.

### Claim 29 (depends on 22)

The method according to claim 22, wherein the molecule has a binding affinity for the serum albumin of less than or equal to 10−13 M.

### Claim 30 (depends on 22)

The method according to claim 22, wherein the molecule has a binding affinity for the serum albumin of less than or equal to 10−14 M.

### Claim 31 (depends on 1)

The method of claim 1, wherein the mammal is a human being.

### Claim 32 (depends on 1)

The method according to claim 1, wherein the mammal is a non-human mammal.

### Claim 33 (depends on 1)

The method according to claim 1, wherein the immune response is a humoral immune response.

### Claim 34 (depends on 1)

The method according to claim 1, wherein the biological activity of the biologically active protein comprises an ability to interact with a target molecule other than a serum albumin.

### Claim 35 (depends on 34)

The method according to claim 34, wherein the biological activity of the biologically active protein comprises an ability to block the activity of the target molecule.

### Claim 36 (depends on 34)

The method according to claim 34, wherein the target molecule is present on the surface of a cell.

### Claim 37 (depends on 36)

The method according to claim 36, wherein the cell is a cancerous or precancerous cell.

### Claim 38 (depends on 37)

The method according to claim 37, wherein the target molecule present on the surface of the cell is selected from HER2, CD4, CD20, CD22, CD74, CEA and EpCAM.

### Claim 39 (depends on 34)

The method according to claim 34, wherein the target molecule is an enzyme.

### Claim 40 (depends on 34)

The method according to claim 34, wherein the target molecule is selected from hormone receptors and cytokine receptors.

### Claim 41 (depends on 34)

The method according to claim 34, wherein the target molecule is a toxin.

### Claim 42 (depends on 41)

The method according to claim 41 in which the toxin is a snake toxin.

### Claim 43 (depends on 1)

The method according to claim 1, wherein the biologically active protein is selected from antibodies and fragments and derivatives thereof, staphylococcal protein A and fragments and derivatives thereof, fibronectin and fragments and derivatives thereof, lipocalin and fragments and derivatives thereof, transferrin and fragments and derivatives thereof, and lectin and fragments and derivatives thereof.

### Claim 44 (depends on 43)

The method according to claim 43, wherein the biologically active protein is staphylococcal protein A, or a biologically active fragment or derivative thereof.

### Claim 45 (depends on 44)

The method according to claim 44, wherein the biologically active protein comprises the B domain of staphylococcal protein A or the protein Z derivative thereof, or a variant thereof having an altered binding affinity.

### Claim 46 (depends on 1)

The method according to claim 1, wherein the biological activity of the biologically active protein comprises an enzymatic activity.

### Claim 47 (depends on 1)

The method according to claim 1, wherein the biological activity of the biologically active protein comprises a hormone activity.

### Claim 48 (depends on 1)

The method according to claim 1, wherein the biological activity of the biologically active protein comprises a pharmaceutical activity.

### Claim 49 (depends on 1)

The method according to claim 1, wherein the biologically active protein is selected from growth hormone, ciliary neurotrophic factor, granulocyte-macrophage colony stimulating factor, insulin, interferon β, factor VIII, erythropoietin, GL1P and thrombopoietin.

### Claim 50

Method of reducing or eliminating the immune response elicited upon administration of a biologically active protein to a human or non-human mammal, which comprises coupling the protein or a biologically active fragment or derivative thereof to at least one moiety capable of binding to a serum albumin of the mammal to form a conjugate, and administering the conjugate to the mammal.

### Claim 51

Method of reducing or eliminating the immune response elicited upon administration of a biologically active protein to a human or non-human mammal, which comprises forming a molecule including the protein or a biologically active fragment or derivative thereof and at least one moiety capable of binding to a serum albumin of the mammal and administering the molecule to the mammal.

### Claim 52

(canceled)

### Claim 53

(canceled)

### Claim 54

An improvement in a method of administering a biologically active protein to a non-human or human mammal, wherein the improvement comprises administering a molecule comprising at least one moiety which is derived from the biologically active protein and at least one moiety capable of binding to a serum albumin of a mammal, whereby the molecule elicits no or a reduced immune response as compared to a compound consisting of the biologically active protein per se.

### Claim 55

(canceled)

### Claim 56

(canceled)

### Claim 57

A molecule comprising at least one moiety which is a biologically active protein and at least one moiety capable of binding to a serum albumin of a mammal, which elicits no or a reduced immune response upon administration to the mammal, as compared to the immune response elicited upon administration to the mammal of the biologically active protein per se.

### Claim 58 (depends on 57)

A molecule according to claim 57 in which the moiety capable of binding to a serum albumin of a mammal comprises a compound selected from proteins and polypeptides.

### Claim 59 (depends on 58)

A molecule according to claim 58, wherein the moiety capable of binding to a serum albumin of a mammal is a naturally occurring polypeptide or an albumin-binding fragment or derivative thereof.

### Claim 60 (depends on 59)

A molecule according to claim 59, wherein the naturally occurring polypeptide is chosen from streptococcal M proteins M1/Emm1, M3/Emm3, M12/Emm12, EmmL55/Emm55, Emm49/EmmL49 and Protein H; streptococcal proteins G, MAG and ZAG; and PPL and PAB from Finegoldia magna.

### Claim 61 (depends on 60)

A molecule according to claim 60, wherein the moiety capable of binding to a serum albumin of a mammal is streptococcal protein G or an albumin-binding fragment or derivative thereof.

### Claim 62 (depends on 61)

A molecule according to claim 61, wherein the moiety capable of binding to a serum albumin of a mammal is the ABD domain of streptococcal protein G, or an albumin-binding fragment or derivative thereof.

### Claim 63 (depends on 59)

A molecule according to claim 59, wherein the moiety capable of binding to a serum albumin of a mammal is an albumin-binding polypeptide comprising from about 5 to about 214 amino acid residues.

### Claim 64 (depends on 63)

A molecule according to claim 63, wherein the moiety capable of binding to a serum albumin of a mammal is an albumin-binding polypeptide comprising from about 5 to about 46 amino acid residues.

### Claim 65 (depends on 64)

A molecule according to claim 64, wherein the albumin-binding polypeptide comprises from about 10 to about 20 amino acid residues.

### Claim 66 (depends on 65)

A molecule according to claim 65, wherein the albumin-binding polypeptide comprises an amino acid sequence selected from DICLPRWGCLW, DLCLRDWGCLW and DICLARWGCLW and albumin-binding derivatives of those sequences.

### Claim 67 (depends on 66)

A molecule according to claim 66, wherein the moiety capable of binding to a serum albumin of a mammal is a non-proteinaceous organic compound.

### Claim 68 (depends on 67)

A molecule according to claim 67, wherein the non-proteinaceous organic compound is selected from albumin-binding non-steroidal anti-inflammatory drugs (NSAIDs); diclofenac; salicylic acid; warfarin; propofol; and halothane.

### Claim 69 (depends on 68)

A molecule according to claim 68 in which the albumin-binding NSAID is ibuprofen or carprofen.

### Claim 70 (depends on 58)

A molecule according to claim 58, wherein the molecule has a first site, which site has a biologically useful activity and a second site, which mediates binding of the molecule to a serum albumin of a mammal.

### Claim 71 (depends on 70)

A molecule according to claim 70 in which the first site is from a biologically active protein.

### Claim 72 (depends on 58)

A molecule according to claim 58, wherein the molecule has a binding affinity for the serum albumin such that the KD of the interaction is less than or equal to 10−6 M.

### Claim 73 (depends on 72)

A molecule according to claim 72, wherein the molecule has a binding affinity for the serum albumin which is less than or equal to 10−7 M.

### Claim 74 (depends on 72)

A molecule according to claim 72, wherein the molecule has a binding affinity for the serum albumin which is less than or equal to 10−8 M.

### Claim 75 (depends on 72)

A molecule according to claim 72, wherein the molecule has a binding affinity for the serum albumin which is less than or equal to 10−9 M.

### Claim 76 (depends on 72)

A molecule according to claim 72, wherein the molecule has a binding affinity for the serum albumin which is less than or equal to 10−10 M.

### Claim 77 (depends on 72)

A molecule according to claim 72, wherein the molecule has a binding affinity for the serum albumin which is less than or equal to 10−11 M.

### Claim 78 (depends on 72)

A molecule according to claim 72, wherein the molecule has a binding affinity for the serum albumin which is less than or equal to 10−12 M.

### Claim 79 (depends on 72)

A molecule according to claim 72, wherein the molecule has a binding affinity for the serum albumin which is less than or equal to 10−13 M.

### Claim 80 (depends on 72)

A molecule according to claim 72, wherein the molecule has a binding affinity for the serum albumin which is less than or equal to 10−14 M.

### Claim 81 (depends on 57)

A molecule according to claim 57, wherein the mammal is a human being.

### Claim 82 (depends on 57)

A molecule according to claim 57, wherein the mammal is a non-human mammal.

### Claim 83 (depends on 57)

A molecule according to claim 57, wherein the immune response is a humoral immune response.

### Claim 84 (depends on 57)

A molecule according to claim 57, wherein the biological activity of the biologically active protein comprises an ability to interact with a target molecule other than a serum albumin.

### Claim 85 (depends on 84)

A molecule according to claim 84, wherein the biological activity of the biologically active protein comprises an ability to block the activity of the target molecule.

### Claim 86 (depends on 84)

A molecule according to claim 84, wherein the target molecule is present on the surface of a cell.

### Claim 87 (depends on 86)

A molecule according to claim 86, wherein the cell is a cancerous or precancerous cell.

### Claim 88 (depends on 87)

A molecule according to claim 87, wherein the target molecule present on the surface of the cell is selected from HER2, CD4, CD20, CD22, CD74, CEA and EpCAM.

### Claim 89 (depends on 88)

A molecule according to claim 88 and in which the target molecule is HER2 or an analogue thereof in which the amino acid sequence of the biologically active protein is VDNKFNKELRQAYWEIQALP NLNWTQSRAF IRSLYDDPSQ SANLLAEAKK LNDAQAPK or a HER2 binding analogue thereof.

### Claim 90 (depends on 85)

A molecule according to claim 85, wherein the target molecule is an enzyme.

### Claim 91 (depends on 85)

A molecule according to claim 85, wherein the target molecule is selected from hormone receptors and cytokine receptors.

### Claim 92 (depends on 57)

A molecule according to claim 57, wherein the biologically active protein is selected from antibodies and fragments and derivatives thereof, staphylococcal protein A and fragments and derivatives thereof, fibronectin and fragments and derivatives thereof, lipocalin and fragments and derivatives thereof, transferrin and fragments and derivatives thereof, and lectin and fragments and derivatives thereof.

### Claim 93 (depends on 92)

A molecule according to claim 92, wherein the biologically active protein is staphylococcal protein A, or a fragment or derivative thereof.

### Claim 94 (depends on 92)

A molecule according to claim 92, wherein the biologically active protein comprises the B domain of staphylococcal protein A or the protein Z derivative thereof, or a variant thereof having an altered binding affinity.

### Claim 95 (depends on 57)

A molecule according to claim 57, wherein the biological activity of the biologically active protein comprises an enzymatic activity.

### Claim 96 (depends on 57)

A molecule according to claim 57, wherein the biological activity of the biologically active protein comprises a hormone activity.

### Claim 97 (depends on 57)

A molecule according to claim 57, wherein the biological activity of the biologically active protein comprises a pharmaceutical activity.

### Claim 98 (depends on 57)

A molecule according to claim 57, wherein the biologically active protein is selected from growth hormone, ciliary neurotrophic factor, granulocyte-macrophage colony stimulating factor, insulin, interferon beta, factor VIII, erythropoietin, GL1P and thrombopoietin.

### Claim 99

A molecule selected from ZTaq4:1-ABD, ABD-Zher2:4, ABD-(Zher2:4)2, ABD-(Zher2:4)3, [ ,]ABD-(Zher2:4)4, (ZAβ3)2, ABD- and (ZAβ3)2.

### Claim 100 (depends on 57)

A molecule according to claim 57 in which the moiety capable of binding to a serum albumin of a mammal is capable of interacting at least one of, and preferably all of, residues Phe-228, Ala-229, Ala-322, Val-325, Phe-326, and Met-329 from human serum albumin so as to enhance binding of the molecule to albumin.

### Claim 101 (depends on 57)

A molecule according to claim 57 in which the moiety capable of binding to a serum albumin of a mammal includes an amino acid residue which forms an interaction with the methionine residue at position 329 of human serum albumin so as to enhance binding of the molecule to albumin.

### Claim 102 (depends on 57)

A molecule according to claim 57 in which the moiety capable of binding to a serum albumin of a mammal includes an amino acid residue which forms an interaction with helix 7 in the human serum albumin domain IIB so as to enhance binding of the molecule to albumin.

### Claim 103 (depends on 57)

A molecule according to claim 57 in which the moiety capable of binding to a serum albumin of a mammal includes an amino acid residue which forms an interaction with residues in human serum albumin domain IIA so as to enhance binding of the molecule to albumin.

### Claim 104 (depends on 57)

A molecule according to claim 57 in which the moiety capable of binding to a serum albumin of a mammal includes an amino acid residue which forms an interaction with residues between helices 2 and 3 of human serum albumin so as to enhance binding of the molecule to albumin.

### Claim 105 (depends on 57)

A composition comprising a molecule according to claim 57 and a pharmaceutically acceptable carrier.

### Claim 106

(canceled)

### Claim 107 (depends on 84)

A complex comprising a molecule according to claim 84 and its target molecule.

### Claim 108 (depends on 57)

A nucleic acid encoding a molecule according to claim 57.

### Claim 109

(canceled)

### Claim 110

(canceled)

### Claim 111 (depends on 50)

The method according to claim 50, wherein the moiety capable of binding to a serum albumin of a mammal is a compound selected from proteins and polypeptides.

### Claim 112 (depends on 111)

The method according to claim 111, wherein the moiety capable of binding to a serum albumin of a mammal is a naturally occurring polypeptide or an albumin-binding fragment or derivative thereof.

### Claim 113 (depends on 112)

The method according to claim 112, wherein the naturally occurring polypeptide is selected from the group consisting of streptococcal M proteins M1/Emm1, M3/Emm3, M12/Emm12, EmmL55/Emm55, Emm49/EmmL49 and Protein H; streptococcal proteins G, MAG and ZAG; and PPL and PAB from Finegoldia magna.

### Claim 114 (depends on 113)

The method according to claim 113, wherein the moiety capable of binding to a serum albumin of a mammal is streptococcal protein G or an albumin-binding fragment or derivative thereof.

### Claim 115 (depends on 114)

The method according to claim 114, wherein the moiety capable of binding to a serum albumin of a mammal is the ABD domain of streptococcal protein G, or an albumin-binding fragment or derivative thereof.

### Claim 116 (depends on 111)

The method according to claim 111, wherein the moiety capable of binding to a serum albumin of a mammal is an albumin-binding polypeptide comprising from about 5 to about 214 amino acid residues.

### Claim 117 (depends on 116)

The method according to claim 116 in which the albumin-binding polypeptide comprises from about 5 to about 46 amino acid residues

### Claim 118 (depends on 116)

The method according to claim 116, wherein the albumin-binding peptide comprises from about 10 to about 20 amino acid residues.

### Claim 119 (depends on 118)

The method according to claim 118, wherein the albumin-binding peptide comprises an amino acid sequence selected from DICLPRWGCLW, DLCLRDWGCLW and DICLARWGCLW and albumin-binding derivatives thereof.

### Claim 120 (depends on 50)

The method of claim 50, in which the moiety capable of binding to a serum albumin of a mammal, is arranged to enhance its binding with human serum albumin.

### Claim 121 (depends on 120)

The method according to claim 120 in which the moiety capable of binding to a serum albumin of a mammal is capable of interacting at least one of, and preferably all of, residues Phe-228, Ala-229, Ala-322, Val-325, Phe-326, and Met-329 from human serum albumin so as to enhance binding of the molecule to albumin.

### Claim 122 (depends on 121)

The method according to claim 121 in which the moiety capable of binding to a serum albumin of a mammal includes an amino acid residue which forms an interaction with the methionine residue at position 329 of human serum albumin so as to enhance binding of the molecule to albumin.

### Claim 123 (depends on 120)

The method according to claim 120 in which the moiety capable of a serum albumin of a mammal includes an amino acid residue which forms an interaction with helix 7 in the human serum albumin domain IIB so as to enhance binding of the molecule to albumin.

### Claim 124 (depends on 120)

The method according to claim 120 in which the moiety capable of binding to a serum albumin of a mammal includes an amino acid residue which forms an interaction with residues in human serum albumin domain IIA so as to enhance binding of the molecule to albumin.

### Claim 125 (depends on 120)

The method according to claim 120 in which the moiety capable of binding to a serum albumin of a mammal includes an amino acid residue which forms an interaction with residues between helices 2 and 3 of human serum albumin so as to enhance binding of the molecule to albumin.

### Claim 126 (depends on 50)

The method according to claim 50, wherein the moiety capable of binding to a serum albumin of a mammal is a non-proteinaceous organic compound.

### Claim 127 (depends on 126)

The method according to claim 126, wherein the non-proteinaceous organic compound is selected from albumin-binding non-steroidal anti-inflammatory drugs (NSAIDs); diclofenac; salicylic acid; warfarin; propofol; and halothane.

### Claim 128 (depends on 127)

The method according to claim 127 in which the albumin-binding NSAID is ibuprofen or carprofen.

### Claim 129 (depends on 50)

The method according to claim 50, wherein the molecule has a first site, which site has a biologically useful activity, and a second site, which mediates binding of the molecule to a serum albumin of a mammal.

### Claim 130 (depends on 129)

The method according to claim 129 in which the first site is from a biologically active protein.

### Claim 131 (depends on 50)

The method according to claim 50, wherein the molecule has a binding affinity for the serum albumin such that the KD of the interaction is less than or equal to 10−6 M.

### Claim 132 (depends on 131)

The method according to claim 131, wherein the molecule has a binding affinity for the serum albumin of less than or equal to 10−7 M.

### Claim 133 (depends on 131)

The method according to claim 131, wherein the molecule has a binding affinity for the serum albumin of less than or equal to 10−8 M.

### Claim 134 (depends on 131)

The method according to claim 131, wherein the molecule has a binding affinity for the serum albumin of less than or equal to 10−9 M.

### Claim 135 (depends on 131)

The method according to claim 131, wherein the molecule has a binding affinity for the serum albumin of less than or equal to 10−10 M.

### Claim 136 (depends on 131)

The method according to claim 131, wherein the molecule has a binding affinity for the serum albumin of less than or equal to 10−11 M.

### Claim 137 (depends on 131)

The method according to claim 131, wherein the molecule has a binding affinity for the serum albumin of less than or equal to 10−12 M.

### Claim 138 (depends on 131)

The method according to claim 131, wherein the molecule has a binding affinity for the serum albumin of less than or equal to 10−13 M.

### Claim 139 (depends on 131)

The method according to claim 131, wherein the molecule has a binding affinity for the serum albumin of less than or equal to 10−14 M.

### Claim 140 (depends on 50)

The method of claim 50, wherein the mammal is a human being.

### Claim 141 (depends on 50)

The method according to claim 50, wherein the mammal is a non-human mammal.

### Claim 142 (depends on 50)

The method according to claim 50, wherein the immune response is a humoral immune response.

### Claim 143 (depends on 50)

The method according to claim 50, wherein the biological activity of the biologically active protein comprises an ability to interact with a target molecule other than a serum albumin.

### Claim 144 (depends on 143)

The method according to claim 143, wherein the biological activity of the biologically active protein comprises an ability to block the activity of the target molecule.

### Claim 145 (depends on 143)

The method according to claim 143, wherein the target molecule is present on the surface of a cell.

### Claim 146 (depends on 145)

The method according to claim 145, wherein the cell is a cancerous or precancerous cell.

### Claim 147 (depends on 146)

The method according to claim 146, wherein the target molecule present on the surface of the cell is selected from HER2, CD4, CD20, CD22, CD74, CEA and EpCAM.

### Claim 148 (depends on 143)

The method according to claim 143, wherein the target molecule is an enzyme.

### Claim 149 (depends on 143)

The method according to claim 143, wherein the target molecule is selected from hormone receptors and cytokine receptors.

### Claim 150 (depends on 143)

The method according to claim 143, wherein the target molecule is a toxin.

### Claim 151 (depends on 150)

The method according to claim 150 in which the toxin is a snake toxin.

### Claim 152 (depends on 50)

The method according to claim 50, wherein the biologically active protein is selected from antibodies and fragments and derivatives thereof, staphylococcal protein A and fragments and derivatives thereof, fibronectin and fragments and derivatives thereof, lipocalin and fragments and derivatives thereof, transferrin and fragments and derivatives thereof, and lectin and fragments and derivatives thereof.

### Claim 153 (depends on 152)

The method according to claim 152, wherein the biologically active protein is staphylococcal protein A, or a biologically active fragment or derivative thereof.

### Claim 154 (depends on 153)

The method according to claim 153, wherein the biologically active protein comprises the B domain of staphylococcal protein A or the protein Z derivative thereof, or a variant thereof having an altered binding affinity.

### Claim 155 (depends on 50)

The method according to claim 50, wherein the biological activity of the biologically active protein comprises an enzymatic activity.

### Claim 156 (depends on 50)

The method according to claim 50, wherein the biological activity of the biologically active protein comprises a hormone activity.

### Claim 157 (depends on 50)

The method according to claim 50, wherein the biological activity of the biologically active protein comprises a pharmaceutical activity.

### Claim 158 (depends on 50)

The method according to claim 50, wherein the biologically active protein is selected from growth hormone, ciliary neurotrophic factor, granulocyte-macrophage colony stimulating factor, insulin, interferon β, factor VIII, erythropoietin, GL1P and thrombopoietin.
